Dossier assessment
Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Repotrectinib (NSCLC) Benefit assessment according to §35a SGB V
-
Dossier assessment
Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Monotherapy for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer
Result of dossier assessment:
- Patients who have not previously received a ROS1 inhibitor: added benefit not proven
- Patients who have previously received a ROS1 inhibitor and with a programmed cell death ligand 1 expression ≥ 50%: added benefit not proven
- Patients who have previously received a ROS1 inhibitor and with a programmed cell death ligand 1 expression < 50%: added benefit not proven
Project details
- Project no.
- A25-59
- Commission
- Commission awarded on 30.04.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A25-59
Connected Projects
-
Dossier assessment
Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed